Physician profile
Anna Chernyak
NPI 1558437665
$8,208.35
in general payments reported to CMS, 2019-2025
37 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $1,163 · 2021: $1,511 · 2022: $1,265 · 2023: $1,019 · 2024: $1,007 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,944.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,115.16 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,022.29 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $378.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $372.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $364.96 | 2019-2023 | Xarelto |
| Amgen INC. | $359.12 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $303.35 | 2019-2023 | |
| Novo Nordisk INC | $248.41 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $232.92 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $195.67 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $177.03 | 2021-2023 | |
| Exact Sciences Corporation | $169.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Indivior INC. | $160.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $137.57 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Chernyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.